Marshall Wace
SWTX

Marshall Wace’s SpringWorks Therapeutics SWTX Stock Holding History

Marshall Wace’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-185,540
Closed -$8.72M – 3385
2025
Q2 		$8.72M Buy
185,540
+134,602
+264% +$5.99M 0.01% 901
2025
Q1 		$2.25M Buy
+50,938
New +$2.34M ﹤0.01% 1423
2024
Q4 		– Sell
-1,961,830
Closed -$62.9M – 2995
2024
Q3 		$62.9M Sell
1,961,830
-371,287
-16% -$13.9M 0.08% 229
2024
Q2 		$87.9M Sell
2,333,117
-633,505
-21% -$26.7M 0.12% 163
2024
Q1 		$146M Sell
2,966,622
-58,237
-2% -$2.69M 0.22% 84
2023
Q4 		$110M Buy
3,024,859
+1,736,606
+135% +$45.3M 0.19% 105
2023
Q3 		$29.8M Buy
1,288,253
+80,613
+7% +$2.2M 0.06% 325
2023
Q2 		$31.7M Buy
1,207,640
+1,023,306
+555% +$26.9M 0.06% 325
2023
Q1 		$4.74M Buy
+184,334
New +$5.39M 0.01% 1027
2022
Q2 		– Sell
-704,597
Closed -$39.8M – 3829
2022
Q1 		$39.8M Buy
704,597
+297,078
+73% +$17M 0.08% 289
2021
Q4 		$25.3M Buy
407,519
+386,626
+1,851% +$25.6M 0.05% 412
2021
Q3 		$1.32M Buy
+20,893
New +$1.61M 0.01% 1827
2021
Q2 		– Sell
-65,044
Closed -$4.79M – 3076
2021
Q1 		$4.79M Buy
+65,044
New +$5.09M 0.02% 867

Other funds holding SWTX

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Marshall Wace's SWTX Position: Q3 2025 in Review

Marshall Wace sold out of SpringWorks Therapeutics (SWTX) in Q3 2025, closing a stake of 185,540 shares — an estimated $8.72M sold.

Marshall Wace first reported a position in SWTX in Q1 2021 and held it in 13 quarters. The position peaked at $146M in Q1 2024. 3 funds tracked by Wall St. Rank hold SWTX as of Q3 2025.

  • Marshall Wace reported no remaining SpringWorks Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Marshall Wace sold 185,540 SpringWorks Therapeutics shares in Q3 2025, an estimated $8.72M.
  • Marshall Wace first reported a position in SpringWorks Therapeutics in Q1 2021 and held it in 13 quarters.
  • Marshall Wace's SpringWorks Therapeutics position peaked at $146M in Q1 2024.
  • 3 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2025.

Based on Marshall Wace's 13F filing for Q3 2025, filed 13 Nov 2025.